Lexaria Bioscience Warrant
LEXXW
LEXXW was delisted on the 13th of January, 2026.
3 hedge funds and large institutions have $109K invested in Lexaria Bioscience Warrant in 2024 Q2 according to their latest regulatory filings, with 0 funds opening new positions, 1 increasing their positions, reducing their positions, and 0 closing their positions.
74% more capital invested
Capital invested by funds: $62.8K → $109K (+$46.4K)
0% more funds holding
Funds holding: 3 → 3 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$106K |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
UBS Group
Zurich,
Switzerland
| $75.5K | +$106K | +93,623 | +94,569% |
|
|
CH
2
CVI Holdings
Wilmington,
Delaware
| $33.6K | – | – | – |
|
|
CS
3
Clear Street
New York
| $81 | – | – | – |
|
LEXXW Hedge Fund Activity: Q2 2024 in Review
3 of the 6,925 institutional investors tracked by Wall St. Rank reported a position in Lexaria Bioscience Warrant (LEXXW) for Q2 2024, worth a combined $109K — up 74% from $62.8K a quarter earlier.
Fund positioning in LEXXW was balanced in Q2 2024: 0 funds opened new positions, 0 closed out, 1 added to existing stakes and 0 trimmed.
The largest buyer was UBS Group, adding an estimated $106K.
- 3 institutional investors held Lexaria Bioscience Warrant (LEXXW) as of Q2 2024, unchanged from Q1 2024.
- Funds reported $109K of Lexaria Bioscience Warrant stock for Q2 2024, up 74% quarter-over-quarter.
- 0 funds opened new Lexaria Bioscience Warrant positions in Q2 2024 and 0 closed out.
- The largest Lexaria Bioscience Warrant buyer in Q2 2024 was UBS Group, an estimated $106K added.
Based on aggregated 13F filings for Q2 2024.